Geode Capital Management
CGON icon

Geode Capital Management’s CG Oncology CGON Stock Holding History

Geode Capital Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153M Buy
2,153,277
+556,413
+35% +$36.4M 0.01% 952
2026
Q1 		$108M Buy
1,596,864
+85,331
+6% +$4.83M 0.01% 1036
2025
Q4 		$62.8M Buy
1,511,533
+38,360
+3% +$1.59M ﹤0.01% 1353
2025
Q3 		$59.4M Buy
1,473,173
+137,736
+10% +$4M ﹤0.01% 1366
2025
Q2 		$34.7M Buy
1,335,437
+56,203
+4% +$1.35M ﹤0.01% 1629
2025
Q1 		$31.3M Buy
1,279,234
+122,564
+11% +$3.45M ﹤0.01% 1644
2024
Q4 		$33.2M Buy
1,156,670
+78,143
+7% +$2.67M ﹤0.01% 1678
2024
Q3 		$40.7M Buy
1,078,527
+528,749
+96% +$18.5M ﹤0.01% 1557
2024
Q2 		$17.4M Buy
549,778
+45,562
+9% +$1.58M ﹤0.01% 2011
2024
Q1 		$22.1M Buy
+504,216
New +$20.6M ﹤0.01% 1870

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Geode Capital Management's CGON Position: Q2 2026 in Review

Geode Capital Management increased its CG Oncology (CGON) stake by 35% in Q2 2026, buying an estimated $36.4M and bringing the position to 2,153,277 shares worth $153M. The position accounts for 0.01% of the portfolio, ranked #952.

Geode Capital Management first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 212 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Geode Capital Management held 2,153,277 shares of CG Oncology worth $153M as of Q2 2026.
  • Geode Capital Management bought 556,413 CG Oncology shares in Q2 2026, an estimated $36.4M.
  • CG Oncology made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #952 holding.
  • Geode Capital Management first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 212 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.